Eko Health, Inc. (Eko) is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes and AI detection platform, SENSORA™. The company’s FDA-cleared technologies are used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

National Institutes of Health

National Institutes of Health (NIH)

Seraph Group

Morningside Venture Investments

Morningside Venture Partners

PROOF Fund

Sand Hill Angels

NTT Venture Capital

Questa Capital Management

Highland Capital Partners

3M New Ventures

Artis Ventures (AV)

DigiTx Partners

Longevity Vision Fund

Eko Health

🎉 We are honored to announce that the FDA has cleared Eko's Low Ejection Fraction (Low EF) AI. For the first time, U.S. healthcare providers can now detect reduced ejection fraction, a key indicator of heart failure, using an Eko stethoscope during routine physical examinations. 

🫀 Developed in collaboration with Mayo Clinic, Eko's Low EF AI marks a major milestone in the early detection of cardiovascular diseases. 

🎙️ Dr. Paul Friedman, Chair of the Department of Cardiovascular Medicine at Mayo Clinic in Rochester, remarked:

"The ability to identify a hidden, potentially life-threatening heart condition using a tool that primary care and subspecialist clinicians are familiar with — the stethoscope — can help us prevent hospitalizations and adverse events. Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations and hopefully help address care in underserved areas."

🎙️ Connor Landgraf, co-founder and CEO of Eko Health, highlighted:

"The stethoscope, the most recognizable symbol of healthcare, touches the lives of an estimated 1 billion people around the globe every year. With Eko's Low EF AI, we've transformed the icon of medicine into an AI-powered heart failure early detection tool that can help improve access to care for millions of patients at a fraction of the time and cost of echocardiography. It's been a privilege to work alongside Mayo Clinic in this groundbreaking endeavor."

📰 Read the full press release here: https://lnkd.in/g6wur3Xb

#healthcare #digitalhealth #AI #cardiology #health

Meet the Eko team at ACP Internal Medicine Meeting at booth 738! #IM2024

Learn how Eko’s software, combined with advanced digital stethoscope technology, can help you detect disease earlier.

Great article by Alex Knapp highlighting the significance of early heart disease detection and the role Eko’s newly FDA-cleareI liId AI can play in expediting it.🫀

"Heart disease remains the number one killer of Americans, with nearly 700,000 people dying each year. Over 6 million Americans are estimated to live with heart conditions–though they may not know it. But about half of them have a risk factor where their heart isn’t pumping blood as effectively as it could be — what doctors call “low ejection fraction.” Catching this early can mean the prevention of more serious heart conditions, but it often goes undetected because there are few symptoms."

🔗 Read the full article here: https://lnkd.in/gfRpRV85

This insightful STAT article by Lizzy Lawrence highlights the recent FDA clearance of Eko’s Low Ejection Fraction Detection AI, a significant milestone in cardiology achieved in collaboration with Mayo Clinic.

Eko's CEO Connor Landgraf, along with Mayo Clinic cardiologists Dr. Paul Friedman and Dr. Demilade Adedinsewo, discussed how the Low EF AI signifies a crucial development in the early detection of heart disease, impacting healthcare both in the U.S. and worldwide.

🔗 Read the full article here: https://lnkd.in/e9hUWbef

Join the Eko Team at #ACC2024 for an illuminating real-world deployment poster session on the success of Eko's AI-enabled Heart Disease Detection Platform, SENSORA™. 

📅 Session 1542 - Innovation, Digital Health, and Technology 18 
🔍 Presentation Title: Real-world Deployment Success of an AI-enabled Heart Disease Detection Platform: a Case Study
🗣️ Featuring: Emileigh Mercer Lastowski, OTR/L
📌 When & Where: April 8, 2024, 12:45 PM - 1:30 PM, Hall B4-5

This case study unveils the remarkable journey of SENSORA™, an AI-powered cardiac disease detection platform, demonstrating its groundbreaking success in real-world clinical settings. With a focus on Valvular Heart Disease (VHD), learn how SENSORA™ was seamlessly integrated into the workflows of high-volume healthcare centers in Miami, FL, showcasing its exceptional ease of use, accuracy, and the transformative potential for early disease detection.

Witness firsthand the compelling evidence of how AI can revolutionize patient care, significantly enhancing the ability to detect mod+ VHD early and potentially saving lives through advanced technology.

For further details, visit the disclosure: https://bit.ly/3xaTm3e

HSTS

DNSSEC

Cloudflare CDN

IPv6

Cloudflare

Stripe v3

Cloudflare Blocked

AWS Cloudfront Chicago IL Edge

hCaptcha

Zoho Hosting

Chief Medical Officer

Adam Saltman

Co-Founder & CEO

Connor Landgraf

Chief Financial Officer

Renee Gaeta

Co-Founder at Rhizo Media

Roann Pao

Subbu Venkatraman

Co-Founder & Head of Education Product

Tyler Crouch

Vice President, Enterprise Marketing

Brit Gould

VP, Clinical Research and Product Testing

Caroline Currie

VP, Sales

Claire Stovall

VP of Finance and Accounting

Diana Emrani

Corey Mulloy

Ryan Drant

Vasudev Bailey

Ann Lee-Karlon

David Schummers

John Chorba

Chris Barton

Nicole Gaskari

VP, Administration

Rachel Cohen

General Counsel

Co-Founder, VP of Education Product

Garrick Mitchell Mitchell

Social Media Marketing Manager

Bryan Humbarger

Senior VP, Commercial

Co-Founder, CEO, Board Member

United States Companies With Less Than $1B in Revenue (Top 10K)

San Francisco Bay Area Companies With More Than 10 Employees (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Series D - Eko Health

Grant - Eko Health

PROOF

Series C - Eko Health

EDBI

Peak XV Partners

Venture Round - Eko Health

Series B - Eko Health

Series A - Eko Health

Dreamit Ventures

Non Equity Assistance - Eko Health

Seed Round - Eko Health

Emeryville

California

United States

North America

Eko Health Granted Category III CPT Code for SENSORA™ AI Heart Disease Detection Platform

CPT code just the start of Eko’s coverage push for Sensora

How IoT is transforming remote patient monitoring

Eko Health captures $41M to expand AI stethoscope business worldwide

Top digital health funding: Sword, Eko Health

The Week’s 10 Biggest Funding Rounds: Xcimer Energy Leads The Way As Big Rounds Dry Up

Eko Health Raises $41M in Series D Funding

Eko Health Raises $41 Million to Scale AI-Driven Heart and Lung Disease Detection

A digital stethoscope that visualizes ECG data and heart rate on its display, supports arrhythmia detection with Eko AI, and offers a durable design with up to 60 hours of battery life.

Combines Littmann cardiology-grade stethoscope with Eko detection software for amplified sound clarity and noise cancellation, suitable for adult and pediatric patients.

An attachment that transforms any stethoscope into a digital tool with 40X amplification and noise cancellation, compatible with Bluetooth for wireless listening.

A mobile application that works with Eko stethoscopes to visualize, record, and share patient heart and lung data.

AI-supported analysis that guides clinicians through exams to check for signs of heart disease, offering AFib, tachycardia, and bradycardia detection.

Offers flexible pricing for bulk purchases of digital stethoscopes by groups, hospitals, and organizations.

Australia

Oceania

South Korea

Asia

Hong Kong

Romania

Europe

HTML5

Facebook Comments

Amazon Route 53

jQuery

Wordpress

Adobe Fonts

F5 NGINX

Google Tag Manager

Vimeo

Marketing Consulting

Happitech is a company focused on health technology, specifically in the domain of heart monitoring.

Happitech

TytoCare is a provider of telehealth and remote medical examination solutions, including cardiac monitoring.

TytoCare

Sonavi Labs is a company specializing in innovative solutions for cardiac monitoring and diagnostics.

Sonavi Labs

iRhythm Tech is a provider of cloud-based cardiac rhythm monitoring devices.

iRhythm Tech

AliveCor is a company focused on cardiac monitoring and the creation of machine learning techniques for heart disease detection.

AliveCor

Cardiologs is a provider of AI-powered cardiac diagnostics and monitoring solutions.

Cardiologs

Broomwell Healthwatch is a company specializing in cardiac monitoring and health technology solutions.

Broomwell Healthwatch

Eko Health is a digital health company that specializes in cardiac monitoring and AI-powered software solutions for improved heart disease screening and management.

news impact assignment basic	general
public peers	general	May 12, 2024 1:30 PM	f53b754c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 12, 2024 8:14 PM	45a318f9
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	a796a589
crunchbase profile	general	Nov 22, 2024 9:29 AM	0d2126db
li profile	general	May 12, 2024 1:30 PM	089bcf1a
translate crunchbase fundingrounds	general	Nov 22, 2024 1:59 PM	0bb5c354
peers	general
news basic	general	May 12, 2024 1:30 PM	1e7de220
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:EKOHEALTH

Eko Health